NIH Support for our upcoming human trials
CIF’s for-profit partner Covalent Immunology Products has recieved a STTR Phase I grant for the Phase I trial of Dr. Sudhir Paul’s “E-vaccine”. This is huge step for CIF and its partners, and shows great public support for our innovative approach towards the first effective HIV vaccine.
Grant Number: 1 R41 AI087527-01
Advertisement
